Imlygic is the first oncolytic immunotherapy to demonstrate therapeutic benefit for patients with advanced melanoma
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending that Imlygic ( Talimogene laherparepvec ) be granted ap ...
read article